![](/img/cover-not-exists.png)
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon
Zaher K. Otrock, Rami A. Mahfouz, Zahera Fahed…Volume:
96
Language:
english
DOI:
10.1007/s12185-012-1168-9
Date:
October, 2012
File:
PDF, 167 KB
english, 2012